Magnus Medical develops non-invasive neuromodulation systems for the treatment of severe and treatment-resistant depression using personalized brain network targeting. The company’s platform, SAINT®, is an FDA-cleared transcranial magnetic stimulation (TMS)–based therapy that uses image-guided targeting to deliver accelerated treatment protocols. Its approach focuses on tailoring stimulation to individual brain connectivity patterns rather than relying on standardized stimulation sites.

The technology integrates brain imaging with proprietary targeting methods to identify patient-specific neural networks associated with depression. Stimulation is delivered in an accelerated, multi-session protocol over a shortened treatment window compared to conventional TMS approaches. By aligning stimulation with individualized network architecture, the system aims to improve consistency and therapeutic response while maintaining clinical rigor.

Magnus Medical’s technology is intended for use in specialized clinical settings under professional supervision, targeting adults with major depressive disorder who have not responded adequately to medication or standard therapies. The company positions its platform within regulated clinical care pathways, reflecting a broader shift toward precision, network-based neuromodulation in psychiatry.